24078-23-7

Basic information

• Product Name: 4-ForMyl-3-Methylbenzoic acid
• Synonyms: 4-ForMyl-3-Methylbenzoic acid
• CAS NO: 24078-23-7
• Molecular Formula: C₉H₈O₃
• Molecular Weight: 164.15802
• Mol File: 24078-23-7.mol

Chemical Properties

• Boiling Point: 340.5±30.0 °C(Predicted)
• Appearance: /
• Density: 1.263±0.06 g/cm3(Predicted)
• PKA: 3.85±0.10(Predicted)
• CAS DataBase Reference: 4-ForMyl-3-Methylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ForMyl-3-Methylbenzoic acid(24078-23-7)
• EPA Substance Registry System: 4-ForMyl-3-Methylbenzoic acid(24078-23-7)

Safety Data

• Hazardous Substances Data: 24078-23-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-ForMyl-3-Methylbenzoic acid is used as a key intermediate in the synthesis of novel alkylaminomethyl substituted phenyl and thienyl derivatives. These derivatives have been identified as potent S1PR1 agonists, which are important in the development of drugs targeting various diseases, including multiple sclerosis, autoimmune disorders, and certain types of cancer. The compound's unique structure allows for the creation of new molecules with potential therapeutic properties, making it a valuable asset in the pharmaceutical industry.

Upstream product

• 1187028-45-0 tert-butyl 4-formyl-3-methylbenzoate 
• 347174-28-1 tert-butyl 4-bromo-3-methylbenzoate 
• 7697-28-1 4-bromo-3-methylbenzoic acid 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1621164-75-7 (R)-tert-butyl 2-((7-methyl-2-(2-methyl-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate 
• 1621164-76-8 (S)-tert-butyl 2-((7-methyl-2-(2-methyl-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate 
• 1621164-78-0 (2S,5S)-tert-butyl 5-methyl-2-((7-methyl-2-(2-methyl-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate 
• 1621165-16-9 N-ethyl-4-formyl-3-methylbenzamide 
• 1289048-52-7 4-formyl-N,3-dimethylbenzamide 
• 1187029-03-3 (S)-N-(3-(4-(5-(4-((dimethylamino)methyl)-3-methylphenyl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1187029-04-4 (S)-N-(3-(2-ethyl-4-(5-(4-((ethyl(methyl)amino)methyl)-3-methylphenyl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1187029-05-5 (S)-N-(3-(4-(5-(4-((butyl(methyl)amino)methyl)-3-methylphenyl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1187029-06-6 N-{(S)-3-[2-ethyl-4-(5-{4-[(isobutyl-methyl-amino)-methyl]-3-methyl-phenyl}-[1,2,4]oxadiazol-3-yl)-6-methyl-phenoxy]-2-hydroxy-propyl}-2-hydroxy-acetamide 
• 1187029-07-7 (S)-N-(3-(4-(5-(4-((diethylamino)methyl)-3-methylphenyl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1187029-08-8 (S)-N-(3-(2-ethyl-6-methyl-4-(5-(3-methyl-4-(pyrrolidin-1-ylmethyl)phenyl)-1,2,4-oxadiazol-3-yl)phenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1187029-02-2 (S)-N-(3-(2-ethyl-4-(5-(4-((isobutylamino)methyl)-3-methylphenyl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1187028-61-0 N-((S)-3-{2-ethyl-4-[5-(4-formyl-3-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide 
• 24078-24-8 methyl 4-formyl-3-methylbenzoate 

Relevant articles and documents

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups

In a previous communication we reported on the discovery of alkylamino pyridine derivatives (e.g. 1) as a new class of potent, selective and efficacious S1P1 receptor (S1PR1) agonists. However, more detailed profiling revealed that this compound class is phototoxic in vitro. Here we describe a new class of potent S1PR1 agonists wherein the exocyclic nitrogen was moved away from the pyridine ring (e.g. 11c). Further structural modifications led to the identification of novel alkylaminomethyl substituted phenyl and thienyl derivatives as potent S1PR1 agonists. These new alkylaminomethyl aryl compounds showed no phototoxic potential. Based on their in vivo efficacy and ability to penetrate the brain, the 5-alkyl-aminomethyl thiophenes appeared to be the most interesting class. Potent and selective S1PR1 agonist 20e, for instance, maximally reduced the blood lymphocyte count (LC) for 24 h after oral administration of 10 mg/kg to rat and its brain concentrations reached >500 ng/g over 24 h.

IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF

This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

NOVEL AMINOMETHYL BENZENE DERIVATIVES

The invention relates to novel aminomethyl benzene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. (I) wherein A represents one of the groups (I), (I), (I) and